Latest Communications

16 January 2013
MonoSol Rx Enters Into Licensing Agreement With Vestiq Pharmaceuticals for Zuplenz(R) Oral Soluble Film

19 November 2012
APR Applied Pharma Research ("APR") and Labtec GmbH ("Labtec") announce the European approval of two new Oral Dispersible Film (ODF) based respectively on Olanzapine and Donepezil

05 October 2012
Stellar Pharmaceuticals Launches New Migraine Treatment, CAMBIA®, in $150 Million Canadian Prescription Migraine Market


Pharmaceutical Global Development

APR IS engaged in the research, development, and licensing of added value, technology driven and clinically proven prescription pharmaceuticals.

The innovative business approach based on an integrated vision of technologies available and market opportunities enables APR to select and in-license innovation opportunities or develop internally the whole cycle of research&development bringing to fruition innovative product deliveries to improve patients quality of life.

APR files and obtains worldwide market approval and sells them through an established network of commercial partners globally.




Search results